Literature DB >> 17889651

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.

Mi Sun Jin1, Sung Eun Kim, Jin Young Heo, Mi Eun Lee, Ho Min Kim, Sang-Gi Paik, Hayyoung Lee, Jie-Oh Lee.   

Abstract

TLR2 in association with TLR1 or TLR6 plays an important role in the innate immune response by recognizing microbial lipoproteins and lipopeptides. Here we present the crystal structures of the human TLR1-TLR2-lipopeptide complex and of the mouse TLR2-lipopeptide complex. Binding of the tri-acylated lipopeptide, Pam(3)CSK(4), induced the formation of an "m" shaped heterodimer of the TLR1 and TLR2 ectodomains whereas binding of the di-acylated lipopeptide, Pam(2)CSK(4), did not. The three lipid chains of Pam(3)CSK(4) mediate the heterodimerization of the receptor; the two ester-bound lipid chains are inserted into a pocket in TLR2, while the amide-bound lipid chain is inserted into a hydrophobic channel in TLR1. An extensive hydrogen-bonding network, as well as hydrophobic interactions, between TLR1 and TLR2 further stabilize the heterodimer. We propose that formation of the TLR1-TLR2 heterodimer brings the intracellular TIR domains close to each other to promote dimerization and initiate signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889651     DOI: 10.1016/j.cell.2007.09.008

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  516 in total

1.  A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor gamma.

Authors:  Elizabeth M Long; Alexander C Klimowicz; Heitor A Paula-Neto; Brandie Millen; Donna-Marie McCafferty; Paul Kubes; Stephen M Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Investigation of the differential potentials of TLR agonists to elicit uveitis in mice.

Authors:  Jordan J Allensworth; Stephen R Planck; James T Rosenbaum; Holly L Rosenzweig
Journal:  J Leukoc Biol       Date:  2011-09-20       Impact factor: 4.962

Review 3.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

4.  Cell surface trafficking of TLR1 is differentially regulated by the chaperones PRAT4A and PRAT4B.

Authors:  Bryan E Hart; Richard I Tapping
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

5.  N-acylation of lipoproteins: not when sour.

Authors:  Nienke Buddelmeijer
Journal:  J Bacteriol       Date:  2012-03-30       Impact factor: 3.490

6.  On the origin of the triplet puzzle of homologies in receptor heteromers: Toll-like receptor triplets in different types of receptors.

Authors:  Alexander O Tarakanov; Kjell G Fuxe; Dasiel O Borroto-Escuela
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

7.  Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes.

Authors:  Supriya Shukla; Edward T Richardson; Michael G Drage; W Henry Boom; Clifford V Harding
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

8.  A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis.

Authors:  Sumita Jain; Stephen R Coats; Ana M Chang; Richard P Darveau
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

9.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

Review 10.  Trafficking of endosomal Toll-like receptors.

Authors:  Bettina L Lee; Gregory M Barton
Journal:  Trends Cell Biol       Date:  2014-01-15       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.